





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/813,323	03/10/1997	DAVID BALTIMORE	50659/JPW/JM	3314
75	90 02/12/2002			
JOHN P WHITE COOPER AND DUNHAM 1185 AVENUE OF THE AMERICAS			EXAMINER	
			DAVIS, MINH TAM B	
NEW YORK, NY 10036			ART UNIT	PAPER NUMBER
			1642	26
		DATE MAILED: 02/12/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.

Application N . Applicant(s) 08/813,323 BALTIMORE ET AL.	• "				
Office Action Summary Examiner Art Unit					
L'Adminer Art offic					
MINH-TAM DAVIS 1642					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status	nication.				
1) Responsive to communication(s) filed on 28 November 2001.					
2a)⊠ This action is FINAL . 2b)□ This action is non-final.	action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)⊠ Claim(s) 3,4 and 92 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>3,4 and 92</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12)☐ The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
 a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)					

Application/Control Number: 08/813,323

Art Unit: 1642

Effective February 7, 1998, the Group Art Unit location has been changed, and the examiner of the application has been changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Minh-Tam Davis, Group Art Unit 1642.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Accordingly, claims 3, 4, 92 are being examined.

The following are the remaining rejections.

REJECTION UNDER 35 USC 112, FIRST PARAGRAPH, NEW MATTER

Rejection under 35 USC 112, first paragraph of claims 3, 4, 92 pertaining to lack of a clear written description of an amino-terminal at amino acid 385 remains for reasons already of record in paper No.24.

Applicant asserts that page 8, lines 3-5 of the specification disclose a portion of SEQ ID NO:1, which portion has as its amino-terminal boundary any one of amino acid residues from 324 to 415 of SEQ ID NO:1.

Applicant's arguments set forth in paper No.25 have been considered but are not deemed to be persuasive for the following reasons:

Page 8, lines 3-5 of the specification does not disclose a portion of SEQ ID NO:1, which portion has as its amino-terminal boundary any one of amino acid residues from 324 to 415 of SEQ ID NO:1. Page 8, lines 3-5 of the specification only discloses a

Application/Control Number: 08/813,323

Art Unit: 1642

truncated CRAF1 by from about 323 to about 414 amino acid residues at the amino terminus, or a variant thereof capable of inhibiting CD-40 mediated cell activation.

REJECTION UNDER 35 USC 102

Rejection under 35 USC 102(b) of claims 3, 4, 92 pertaining to anticipation by Sato et al remains for reasons already of record in paper No.24.

Applicant asserts that the protein by Sato et al does not have an amino-terminus between residues 324 and 385 of SEQ ID NO:1. The amino-terminus of Sato protein occurs at residue 387.

Applicant's arguments set forth in paper No.25 have been considered but are not deemed to be persuasive for the following reasons:

The claims do not necessarily read on a protein having an amino-terminus between residues 324 and 385 of SEQ ID NO:1. Thus Applicant argues limitation not in the claims.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any

Application/Control Number: 08/813,323

Art Unit: 1642

اً من کي د شي

3,323 Page 4

extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINH-TAM DAVIS whose telephone number is 703-305-2008. The examiner can normally be reached on 9:30AM-4:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, ANTHONY CAPUTA can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0916.

ANTHONY C. CAPUTA SUPERVISORY PATENT EXAM!NER TECHNOLOGY CENTER 1600

MINH TAM DAVIS

February 7, 2002